Despite major advances in the risk assessment tools for atherosclerotic cardiovascular disease (ASCVD), there is an unmet need to improve these tools beyond the traditional risk factors to capture the residual lipid and inflammatory risks.1–3 There are likely molecular targets beyond lipids that reduce ASCVD risk.2,3 Recent advances in high-throughput proteomics have enabled the characterization of plasma proteins in large-scale studies, thereby promoting proteomics discovery to the forefront of strategies to identify novel biomarkers.
Click here to continue reading: academic.oup.com